GlassScriptPhysician profile
James J Mancuso
NPI 1134303035
$13,571.19
in general payments reported to CMS, 2019-2025
40 companies · $1,866 in 2025
The $1,866 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $761 · 2021: $2,379 · 2022: $2,824 · 2023: $2,767 · 2024: $1,937 · 2025: $1,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,569.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,701.19 | 2019-2025 | |
| Amgen INC. | $1,668.77 | 2019-2025 | Repatha, Repatha |
| Inari Medical, INC. | $1,158.54 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $1,061.98 | 2019-2025 | Farxiga, Brilinta |
| Boston Scientific Corporation | $940.85 | 2019-2025 | Bodyguardian, Cds - Mct/Cem Monitoring |
| Janssen Pharmaceuticals, INC | $878.76 | 2020-2024 | Xarelto |
| Esperion Therapeutics, INC. | $704.97 | 2020-2025 | Nexletol |
| Abiomed | $692.35 | 2020-2025 | Impella |
| Cardiovascular Systems INC. | $506.62 | 2021 | |
| Merck Sharp & Dohme LLC | $501.05 | 2022-2025 | Verquvo, Capvaxive |
| Cvrx, INC. | $356.19 | 2020-2023 | Barostim Neo System |
| Atricure, INC. | $315.96 | 2023-2024 | |
| Pfizer INC. | $273.24 | 2019-2025 | |
| Teleflex LLC | $257.44 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $253.92 | 2022-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $217.91 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.42 | 2020-2024 | Jardiance |
| Novo Nordisk INC | $196.71 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Angiodynamics, INC. | $188.16 | 2022 | |
| Abbott Laboratories | $182.48 | 2021-2025 | Cardiomems |
| Penumbra, INC. | $157.59 | 2023-2024 | Indigo System |
| Regeneron Healthcare Solutions, INC. | $156.58 | 2022-2025 | Evkeeza, Praluent |
| Amarin Pharma, INC. | $127.95 | 2019-2023 | |
| Celonova Biosciences, INC. | $125.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $121.01 | 2019-2023 | |
| Biotronik INC. | $120.83 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.77 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $66.64 | 2022-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $54.69 | 2023-2024 | |
| Daiichi Sankyo INC. | $49.86 | 2023 | Injectafer |
| Cordis US Corp. | $47.84 | 2025 | Mynx Control Venous |
| Actelion Pharmaceuticals US, INC. | $40.36 | 2019-2025 | Uptravi, Opsumit |
| Itamar Medical INC | $25.44 | 2023 | Watchpatone |
| Althera Pharmaceuticals LLC | $23.57 | 2021 | |
| Lilly USA, LLC | $21.97 | 2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $17.80 | 2025 | Keveyis |
| Kiniksa Pharmaceuticals, LTD. | $13.19 | 2023 | Arcalyst |
| Terumo Medical Corporation | $11.78 | 2020 | |
| Philips North America LLC | $11.31 | 2020 | |
| Alexion Pharmaceuticals, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mancuso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.